{"product_id":"bayer-bcg-matrix","title":"Bayer Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix Snapshot - Bayer AG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis preview maps Bayer's life‑science portfolio-pharmaceuticals, crop science and consumer health-onto the BCG Matrix (Stars, Cash Cows, Question Marks, Dogs), showing where growth potential and cash generation intersect with strategic risk. It highlights which divisions drive market share and which may need reinvestment, realignment or divestment. Purchase the full report for a complete breakdown and practical strategic recommendations tailored to Bayer's business lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNubeqa Prostate Cancer Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNubeqa (darolutamide) reached blockbuster status with global sales above 1.5 billion euros by end-2025, growing \u0026gt;75% year-on-year and driving Pharmaceuticals segment revenue growth.\u003c\/p\u003e\n\u003cp\u003eIt's rapidly gaining share as a leading androgen receptor inhibitor for metastatic hormone-sensitive prostate cancer and is a primary growth engine for Bayer.\u003c\/p\u003e\n\u003cp\u003eA third regulatory approval in China is expected in 2026; Bayer is investing heavily in promotion to cement Nubeqa as a standard of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKerendia for Chronic Kidney Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKerendia for Chronic Kidney Disease is a Stars asset: sales surged nearly 87% in 2025 to about EUR 1.1 billion, driven by clear impact in type 2 diabetes patients with kidney disease.\u003c\/p\u003e\n\u003cp\u003eThe product is expanding via new indications, including 2025 priority reviews for heart failure, widening addressable market to ~45 million high-risk patients globally.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Kerendia plus Nubeqa formed Bayer's pharma recovery backbone, contributing roughly EUR 2.3 billion combined sales; continued investment is needed to fend off renal and CV competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDekalb Hybrid Corn Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDekalb Hybrid Corn is a Star in Bayer's BCG matrix, holding a dominant 28% market share in India as of Q4 2025 and delivering double-digit revenue growth with ~22% ROI.\u003c\/p\u003e\n\u003cp\u003eBayer invested heavily in FY 2024-25 to expand global seed processing capacity, raising capex by about €300 million to meet rising demand for high-yield hybrids.\u003c\/p\u003e\n\u003cp\u003eProjected to become a major cash generator for Crop Science, Dekalb's high growth and strong margins support scaling R\u0026amp;D and global commercialization through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEylea 8mg High-Dose\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEylea 8mg High-Dose has defended Bayer's ophthalmology share by cutting dosing frequency, helping patient retention and adherence.\u003c\/p\u003e\n\u003cp\u003eIt showed mid-single-digit global sales growth in 2025, cushioning Bayer from biosimilar pressure on the 2mg dose.\u003c\/p\u003e\n\u003cp\u003eLeading in the growing AMD and diabetic retinopathy markets, it stays a high-value Star backed by strategic marketing and robust clinical data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 growth: ~5-7% global sales rise\u003c\/li\u003e\n\u003cli\u003eFewer injections: extends dosing to Q12 weeks\u003c\/li\u003e\n\u003cli\u003eOffsets 2mg biosimilars\u003c\/li\u003e\n\u003cli\u003eHigh margin specialty product\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElinzanetant Menopause Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElinzanetant Menopause Management launched in late 2025 in the USA and Europe as a first-in-class non-hormonal therapy for vasomotor symptoms, entering a high-growth menopause market forecasted at ~6-8 billion euros by 2028; analysts project peak sales for Elinzanetant to exceed 1 billion euros.\u003c\/p\u003e\n\u003cp\u003eAs a first-to-market innovative product, it needs heavy Bayer support for market access and physician education-estimated launch investment €200-€350M-and, if current uptake holds, is on track to become the Women's Healthcare segment's primary revenue driver by 2027.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch: late 2025 (US, EU)\u003c\/li\u003e\n\u003cli\u003eType: non-hormonal, first-in-class\u003c\/li\u003e\n\u003cli\u003eMarket size: ~€6-8B by 2028\u003c\/li\u003e\n\u003cli\u003ePeak sales: \u0026gt;€1B (analyst consensus)\u003c\/li\u003e\n\u003cli\u003eEstimated launch spend: €200-€350M\u003c\/li\u003e\n\u003cli\u003eKey year: primary driver by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer's Blockbusters Surge: Nubeqa €1.5B, Kerendia €1.1B, Elinzanetant \u0026gt;€1B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer Stars: Nubeqa €1.5B (2025), +75% YoY; Kerendia €1.1B, +87% (2025); Dekalb corn 28% India share, ~22% ROI; Eylea 8mg +5-7% (2025); Elinzanetant launch late‑2025, peak \u0026gt;€1B. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 sales\/metric\u003c\/th\u003e\n\u003cth\u003eGrowth\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNubeqa\u003c\/td\u003e\n\u003ctd\u003e€1.5B\u003c\/td\u003e\n\u003ctd\u003e+75% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKerendia\u003c\/td\u003e\n\u003ctd\u003e€1.1B\u003c\/td\u003e\n\u003ctd\u003e+87% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDekalb\u003c\/td\u003e\n\u003ctd\u003e28% India\u003c\/td\u003e\n\u003ctd\u003e~22% ROI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEylea 8mg\u003c\/td\u003e\n\u003ctd\u003emid‑single %\u003c\/td\u003e\n\u003ctd\u003eQ12 dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElinzanetant\u003c\/td\u003e\n\u003ctd\u003elaunch 2025\u003c\/td\u003e\n\u003ctd\u003epeak \u0026gt;€1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Bayer's portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Bayer BCG Matrix placing each business unit in a quadrant for swift portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXarelto Anticoagulant Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite patent expirations and a 31% sales drop in Q1 2025, Xarelto (rivaroxaban) remains a major cash generator for Bayer, still delivering estimated annual net sales around €3.4 billion in 2024 and funding operations into 2025.\u003c\/p\u003e\n\u003cp\u003eIt holds a leading share in the mature anticoagulation market, requires minimal new capex, and its high cash conversion funds R\u0026amp;D for new launches and supports debt service-Bayer reported net debt of €18.9 billion at end-2024.\u003c\/p\u003e\n\u003cp\u003eAs the quintessential Cash Cow in Bayer's BCG matrix, Xarelto provides the liquidity backbone for the company's turnaround strategy while management milks remaining revenues to preserve margin and free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMirena Contraceptive Family\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Mirena contraceptive family, including Kyleena and Jaydess, stays the market leader in the mature long-acting reversible contraceptive (LARC) segment; in 2025 combined sales grew over 20% year-on-year to roughly €2.6 billion, driven by strong brand loyalty and high gross margins near 80%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArize Hybrid Rice\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArize Hybrid Rice holds a 32% share of the organized hybrid rice market in Asia and contributes about 25% of Bayer Crop Science's regional revenue, with 2024 estimated revenues ~USD 420 million from the brand (here's the quick math: regional Crop Science revenue ~USD 1.68 billion). \u003c\/p\u003e\n\u003cp\u003eHybrid rice is a mature, low-capex market for Bayer, so Arize delivers steady gross margins near 38% and strong operating cash flow, funding R\u0026amp;D in digital ag and gene-editing programs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Health Dermatology Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer's dermatology category, led by Bepanthen (wound care) and Canesten (antifungal), grew 7% in 2025 within a mature self-care market, driven by stable demand and premium pricing.\u003c\/p\u003e\n\u003cp\u003eThese brands hold high consumer trust and top market shares in Europe and Latin America, need maintenance-level investment, and deliver consistent, high-margin cash flows that stabilize Consumer Health results.\u003c\/p\u003e\n\u003cp\u003eThe cash generated funds Bayer's digital transformation and R\u0026amp;D in other consumer segments; here's the quick math: steady margins converting to predictable free cash flow for reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e7% sales growth in 2025\u003c\/li\u003e\n\u003cli\u003eHigh market share in core markets\u003c\/li\u003e\n\u003cli\u003eMaintenance capex only\u003c\/li\u003e\n\u003cli\u003eFunds digital\/innovation spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiology Contrast Media\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer's Radiology Contrast Media unit, anchored by iodinated Ultravist and gadolinium-based Gadovist, stayed a cash cow in 2025 with ~4% volume growth and ~€1.1bn revenue, reflecting entrenched use in clinical imaging worldwide.\u003c\/p\u003e\n\u003cp\u003eThe unit delivered ~25-30% operating margin, low volatility, and predictable free cash flow that funds R\u0026amp;D across Bayer's life‑science portfolio while consistently hitting internal targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 volume +4%\u003c\/li\u003e\n\u003cli\u003eRevenue ~€1.1bn\u003c\/li\u003e\n\u003cli\u003eOp margin 25-30%\u003c\/li\u003e\n\u003cli\u003eStable cash flow, low volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer's 2024-25 cash cows: Xarelto, Mirena, Arize, Derm \u0026amp; Radiology fund R\u0026amp;D \u0026amp; debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXarelto, Mirena family, Arize hybrid rice, dermatology brands (Bepanthen\/Canesten), and Radiology Contrast (Ultravist\/Gadovist) are Bayer cash cows in 2024-25, generating recurring high-margin cash (Xarelto ~€3.4bn 2024; Mirena cluster ~€2.6bn 2025; Arize ~USD420m 2024; Radiology ~€1.1bn 2025) that covers maintenance capex and funds R\u0026amp;D and debt (net debt €18.9bn end‑2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\/unit\u003c\/th\u003e\n\u003cth\u003e2024-25 sales\u003c\/th\u003e\n\u003cth\u003emargin\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXarelto\u003c\/td\u003e\n\u003ctd\u003e€3.4bn (2024)\u003c\/td\u003e\n\u003ctd\u003eHigh cash conv.; patent headwinds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMirena family\u003c\/td\u003e\n\u003ctd\u003e€2.6bn (2025)\u003c\/td\u003e\n\u003ctd\u003e~80% gross margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArize\u003c\/td\u003e\n\u003ctd\u003eUSD420m (2024)\u003c\/td\u003e\n\u003ctd\u003e~38% gross margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDermatology\u003c\/td\u003e\n\u003ctd\u003e- (2025 +7%)\u003c\/td\u003e\n\u003ctd\u003eStable, premium pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiology Contrast\u003c\/td\u003e\n\u003ctd\u003e€1.1bn (2025)\u003c\/td\u003e\n\u003ctd\u003eOp margin 25-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You're Viewing Is Included\u003c\/span\u003e\u003cbr\u003eBayer BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final BCG Matrix you'll receive after purchase-no watermarks, no demo content-just a fully formatted, ready-to-use strategic report built for clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlyphosate-Based Herbicides (Roundup)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe legacy Roundup glyphosate portfolio is a Dogs-category cash trap: stagnant sales and a crippling 7.25 billion euro litigation settlement finalized in 2026 have turned it into a low-growth, high-risk asset despite remaining market share.\u003c\/p\u003e\n\u003cp\u003eBayer faces rising regulatory costs and reputational damage; Group EBIT from crop science fell 12% in 2025, prompting a strategic shift to non-glyphosate alternatives and accelerated R\u0026amp;D spend to exit this segment.\u003c\/p\u003e\n\u003cp\u003eRoundup is now a prime candidate for minimization or divestment as Bayer distances itself from the Monsanto acquisition fallout and reallocates capital to higher-growth seeds and biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinor Non-Strategic Consumer Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer has been divesting minor Consumer Health brands that no longer fit its high-impact self-care focus; in 2024 it sold or discontinued over 20 SKUs, trimming ~€150m in annual sales to boost margins. These Dogs have low market share and face private-label pressure in slow-growth OTC segments, often delivering single-digit revenue growth and negative ROIC. They tie up management time and capital with limited upside, so Dynamic Shared Ownership pushes exit to reallocate resources to core franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Crop Protection Chemicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy crop protection chemicals at Bayer generate shrinking margins and low market growth: global sales of conventional actives fell about 6% in 2024 vs 2021, while biologicals grew ~18% annually, eroding pricing power.\u003c\/p\u003e\n\u003cp\u003eMany older molecules face EU restrictions-over 12 active ingredients were delisted or limited since 2019-so Bayer is de-emphasizing these low-return lines.\u003c\/p\u003e\n\u003cp\u003eThe group is reallocating R\u0026amp;D and capex toward premium, patent-protected molecules; legacy products are being phased out to raise divisional EBITDA margins, which lagged peers by ~250 basis points in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Nutritionals Category\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Nutritionals segment within Bayer Consumer Health fell over 5% in 2025 sales, reflecting weak demand versus rivals and shifting consumer preferences in a mature market where Bayer holds low market share and misses division growth targets.\u003c\/p\u003e\n\u003cp\u003eCostly turnaround initiatives-budgeted at ~€120-150m in 2025-have not reversed trends, positioning Nutritionals as a candidate for restructuring or divestment to stop diluting division margins and ROIC.\u003c\/p\u003e\n\u003cp\u003eIts underperformance drags an otherwise balanced Consumer Health portfolio, reducing segmental EBITDA margin by an estimated 1.2 percentage points in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales decline: \u0026gt;5% in 2025\u003c\/li\u003e\n\u003cli\u003eTurnaround spend: ~€120-150m\u003c\/li\u003e\n\u003cli\u003eEBITDA drag: ~1.2 pp\u003c\/li\u003e\n\u003cli\u003eLow market share in mature category\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Eylea 2mg Dosage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe original Eylea 2mg has moved into a Dog role as biosimilars and Bayer's 8mg high-dose siphon off share; U.S. sales for 2mg fell ~38% YoY in 2024 to an estimated $360M as patents expired and market price pressure intensified.\u003c\/p\u003e\n\u003cp\u003eGrowth for 2mg is flat-to-negative in the mature ophthalmology market; Bayer has cut promotional spend and is harvesting remaining margins while shifting R\u0026amp;D and commercial focus to higher-margin Star candidates (next-gen Star portfolio launches slated 2025-2027).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 sales ~ $360M; -38% YoY\u003c\/li\u003e\n\u003cli\u003ePatent expiries 2023-2024; biosimilar entries 2024\u003c\/li\u003e\n\u003cli\u003eMarketing redirected to Star launches 2025-2027\u003c\/li\u003e\n\u003cli\u003e2mg now managed for residual cash flow, low reinvestment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer's cash-trap \"Dogs\": divest\/trim Roundup, legacy actives, Nutritionals; harvest Eylea\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer's Dogs (legacy Roundup, older crop actives, low-margin Consumer Health Nutritionals, Eylea 2mg) are low-growth, low-share cash traps: 2024-25 sales down \u0026gt;5-38%, €7.25bn Roundup settlement, ~€150m disposed SKU sales trimmed, Nutritionals drag ~1.2pp EBITDA, Eylea 2mg $360M (2024, -38%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024-25 metric\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoundup\u003c\/td\u003e\n\u003ctd\u003e€7.25bn settlement; stagnant sales\u003c\/td\u003e\n\u003ctd\u003eMinimize\/divest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy crop actives\u003c\/td\u003e\n\u003ctd\u003eSales -6% (2021-24)\u003c\/td\u003e\n\u003ctd\u003ePhase out\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutritionals\u003c\/td\u003e\n\u003ctd\u003eSales -5% (2025); EBITDA -1.2pp\u003c\/td\u003e\n\u003ctd\u003eRestructure\/divest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEylea 2mg\u003c\/td\u003e\n\u003ctd\u003e$360M 2024; -38% YoY\u003c\/td\u003e\n\u003ctd\u003eHarvest cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and Gene Therapy Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer's Cell and Gene Therapy (CGT) platform, built via AskBio (acquired 2020) and BlueRock (acquired 2019), sits as a Question Mark: zero current market share but huge upside if trials succeed.\u003c\/p\u003e\n\u003cp\u003eThese units burned ~€600-800M in R\u0026amp;D 2023-2024 combined, funding Phase I\/II programs with high failure risk; commercialization could multiply value if even one program reaches market.\u003c\/p\u003e\n\u003cp\u003eTurning them into Stars needs strategic patience and continued R\u0026amp;D spend-expect multi-year cash burn and milestone-driven valuation jumps if late-stage success arrives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsundexian Stroke Prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAsundexian, Bayer's oral Factor XIa inhibitor in late-stage trials, sits in the Question Mark quadrant because it has near-zero market share but targets the large stroke-prevention market where rivaroxaban (Xarelto) lost exclusivity in 2024; Phase 3 readouts expected 2025-2026 will determine uptake.\u003c\/p\u003e\n\u003cp\u003eIf pivotal trials show noninferior bleeding and superior stroke reduction, peak sales could reach $3-6 billion annually by 2032 based on IMS estimates for anticoagulants; otherwise, heavy R\u0026amp;D and commercial spend will be sunk costs against entrenched rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming and Climate FieldView\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClimate FieldView is a high-growth digital farming platform with single-digit market share versus legacy seed\/chemicals; global digital ag revenue hit about $4.6B in 2024 with regenerative tools growing ~18% CAGR, so FieldView sits in Question Marks.\u003c\/p\u003e\n\u003cp\u003eBayer must invest hundreds of millions in software and data integration-Bayer Digital \u0026amp; Brand spent ≈€300M in 2023-plus partnerships and subsidies to drive farmer adoption and move FieldView into Stars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological Crop Protection Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer is building Biological Crop Protection Solutions and carbon-farming offerings-high-growth niches-though they currently account for under 3% of 2024 EUR 43.5bn group revenue, facing strong startup competition and requiring heavy farmer education and marketing to scale.\u003c\/p\u003e\n\u003cp\u003eIf Bayer scales these green solutions, they can move from Question Marks to Stars, potentially capturing share in markets growing at 10-15% CAGR (biologicals) and supporting net-zero goals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiologicals \u0026lt;3% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eSector CAGR ~10-15%\u003c\/li\u003e\n\u003cli\u003eHigh customer education cost\u003c\/li\u003e\n\u003cli\u003eStrong startup competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeyonttra for ATTR-CM Cardiology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBeyonttra (acoramidis) targets EU launch 2025\/2026 for transthyretin amyloid cardiomyopathy (ATTR-CM); market growth projected ~12-15% CAGR through 2030 and addressable patient count ~50-70k in EU5. As a new entrant it has low initial share versus tafamidis and inotersen, so it's a Question Mark consuming heavy launch and regulatory spend-estimated €200-€400M early investment-but could deliver high returns if it captures 10-20% market, turning into a Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch: EU 2025\/2026\u003c\/li\u003e\n\u003cli\u003eAddressable patients: ~50-70k (EU5)\u003c\/li\u003e\n\u003cli\u003eMarket growth: ~12-15% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eEarly investment: approx €200-€400M\u003c\/li\u003e\n\u003cli\u003eTarget share to become Star: 10-20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer's Question Marks: €1.2-1.5bn R\u0026amp;D, big upside vs low current share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer's Question Marks (CGT, asundexian, FieldView, biologicals, Beyonttra) have low current share but high upside; combined 2023-24 R\u0026amp;D\/commercial spend ~€1.2-1.5bn, potential peak sales per asset $3-6bn (asundexian) or €0.5-1.5bn (Beyonttra); biologicals \u0026lt;3% of €43.5bn 2024 revenue; digital ag market €4.6bn (2024), ~18% regen CAGR.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 spend\u003c\/th\u003e\n\u003cth\u003ePeak sales est.\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGT\u003c\/td\u003e\n\u003ctd\u003e€600-800M\u003c\/td\u003e\n\u003ctd\u003e€1-5bn\u003c\/td\u003e\n\u003ctd\u003eHigh failure risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsundexian\u003c\/td\u003e\n\u003ctd\u003e€100-200M\u003c\/td\u003e\n\u003ctd\u003e$3-6bn\u003c\/td\u003e\n\u003ctd\u003eP3 2025-26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView\u003c\/td\u003e\n\u003ctd\u003e€300M\u003c\/td\u003e\n\u003ctd\u003e€0.5-1.5bn\u003c\/td\u003e\n\u003ctd\u003eDigital ag €4.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologicals\u003c\/td\u003e\n\u003ctd\u003e€50-150M\u003c\/td\u003e\n\u003ctd\u003e€1-3bn\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeyonttra\u003c\/td\u003e\n\u003ctd\u003e€200-400M\u003c\/td\u003e\n\u003ctd\u003e€0.5-1.5bn\u003c\/td\u003e\n\u003ctd\u003eEU launch 2025-26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509034545235,"sku":"bayer-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/bayer-bcg-matrix.webp?v=1776711768","url":"https:\/\/bcgmatrixtemplate.com\/products\/bayer-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}